In an effort to better understand a certain disease-causing enzyme, British researchers have created a "map" of more than 100 proteins this enzyme is known to affect. They then identified a druglike molecule that blocks this enzyme to preserve these essential proteins.
In late 2014, the push to develop universal companion diagnostics to facilitate personal treatments for multiple cancers appears to be accelerating.
The U.K.'s Inivata raised more than $6.5 million in new financing to help advance its use of circulating tumor DNA to improve cancer testing and treatment.
Conventional drug testing methods for cancer drugs are often unreliable. In vitro studies don't replicate the complex microenvironment surrounding tumors accurately, and oftentimes, animal research doesn't accurately show how therapies might work in people.
A Utah company will rely on a Japanese pharmaceutical partner to help develop and bring to market its diagnostic imaging biomarker for breast and prostate cancer, and potentially other tumors.
The U.K.'s Abcodia will work with California-based OncoCyte to perfect a blood test for early breast cancer detection.
St. Jude Children's Research Hospital and colleagues from around the country used next-generation sequencing in a study that could upend how a high-risk leukemia subtype is diagnosed and treated in children and adolescents.
Drugs such as Roche/Genentech's Avastin (bevacizumab) boost the survival odds of some ovarian cancer patients but not others. Researchers from The University of Manchester in the U.K. and colleagues believe they've developed a new blood test that can help find patients for whom the drug works best.
A bacteria-based injectable therapy shrunk tumors and completely eradicated others when tested in dogs and rats, according to a new study.
Cancer Genetics isn't making money yet. But the New Jersey developer of DNA-based cancer diagnostics closed out its 2014 second quarter with smaller losses, some strategic acquisitions and a biomarker development partnership with AstraZeneca.